MX2022016236A - Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. - Google Patents
Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.Info
- Publication number
- MX2022016236A MX2022016236A MX2022016236A MX2022016236A MX2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A MX 2022016236 A MX2022016236 A MX 2022016236A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- spectrum disorder
- neuromyelitis optica
- optica spectrum
- treating
- Prior art date
Links
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 title abstract 5
- 208000008795 neuromyelitis optica Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 abstract 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016236A true MX2022016236A (es) | 2023-03-29 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016236A MX2022016236A (es) | 2020-06-30 | 2021-06-30 | Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (enExample) |
| EP (1) | EP4172211A4 (enExample) |
| JP (1) | JP2023534916A (enExample) |
| KR (1) | KR20230030642A (enExample) |
| CN (1) | CN116234571A (enExample) |
| AU (1) | AU2021299307A1 (enExample) |
| BR (1) | BR112022026747A2 (enExample) |
| CA (1) | CA3178954A1 (enExample) |
| IL (1) | IL299381A (enExample) |
| MX (1) | MX2022016236A (enExample) |
| WO (1) | WO2022006283A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230097118A (ko) * | 2020-10-29 | 2023-06-30 | 비엘라 바이오, 인크. | 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용 |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021020924A2 (pt) * | 2019-04-24 | 2022-04-19 | Viela Bio Inc | Uso de um anticorpo anti-cd19 para tratar doença autoimune |
| KR20230097118A (ko) * | 2020-10-29 | 2023-06-30 | 비엘라 바이오, 인크. | 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용 |
-
2021
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022006283A2 (en) | 2022-01-06 |
| AU2021299307A1 (en) | 2022-12-22 |
| US20230406928A1 (en) | 2023-12-21 |
| EP4172211A2 (en) | 2023-05-03 |
| JP2023534916A (ja) | 2023-08-15 |
| WO2022006283A3 (en) | 2022-02-03 |
| EP4172211A4 (en) | 2024-07-10 |
| CA3178954A1 (en) | 2022-01-06 |
| IL299381A (en) | 2023-02-01 |
| KR20230030642A (ko) | 2023-03-06 |
| CN116234571A (zh) | 2023-06-06 |
| BR112022026747A2 (pt) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016236A (es) | Metodos de tratamiento del trastorno del espectro de la neuromielitis optica. | |
| MX2022011141A (es) | Anticuerpos anti-coronavirus y metodos de uso. | |
| EA201991157A1 (ru) | Доставка белков на основе бактерий, аттенуированных по вирулентности | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| BRPI0515884A (pt) | métodos de diagnóstico e tratamento de complicações da gravidez | |
| ES2668926T3 (es) | Composición de ARN para el tratamiento del cáncer pulmonar de células no pequeñas (NSCLC) | |
| MX2022016061A (es) | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. | |
| WO2020185541A3 (en) | Zilucoplan as deep tissue penetrating c5 inhibitor | |
| WO2021188881A3 (en) | Compositions and methods for detecting and treating sars-cov-2 | |
| WO2020209988A3 (en) | Diverse marker panel for ptsd diagnosis and treatment | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| WO2021257816A3 (en) | Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury | |
| WO2019241730A8 (en) | Increasing immune activity through modulation of postcellular signaling factors | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| WO2021195470A3 (en) | Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2 | |
| MX2022011050A (es) | Anticuerpos anti-cd36 y su uso para tratar cancer. | |
| EA202092487A1 (ru) | Ферменты кинурениназы человека и их применение | |
| BR112013019674A2 (pt) | método para remoção de metoxipirazinas de vinho e/ou suco, para a remoção de compostos indesejáveis no vinho e/ou suco, para a modificação do perfil organoléptico de vinho e/ou suco e para a remoção de um composto-alvo de vinho e/ou suco | |
| WO2022235551A3 (en) | Fc-fusion protein therapeutic for the treatment of pancreatitis | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| MX2025004473A (es) | Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos | |
| WO2019066620A3 (ko) | 항 c-met 항체 및 이의 용도 | |
| MX2024015079A (es) | Moduladores de rxfp1 para el tratamiento de la hipertension resistente o la insuficiencia cardiaca con hipertension pulmonar | |
| WO2022238542A3 (en) | Krab-containing zinc finger protein and cancer | |
| ZA202107917B (en) | Methods of treating borderline personality disorder |